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ABSTRACT
Introduction: Acute lung injury (ALI) is a devastating
condition that places a heavy burden on public health
resources. Although the need for effective ALI
prevention strategies is increasingly recognised, no
effective preventative strategies exist. The Lung Injury
Prevention Study with Aspirin (LIPS-A) aims to test
whether aspirin (ASA) could prevent and/or mitigate
the development of ALI.
Methods and analysis: LIPS-A is a multicentre,
double-blind, randomised clinical trial testing the
hypothesis that the early administration of ASA will
result in a reduced incidence of ALI in adult patients at
high risk. This investigation will enrol 400 study
participants from 14 hospitals across the USA.
Conditional logistic regression will be used to test the
primary hypothesis that early ASA administration will
decrease the incidence of ALI.
Ethics and dissemination: Safety oversight will be
under the direction of an independent Data and Safety
Monitoring Board (DSMB). Approval of the protocol
was obtained from the DSMB prior to enrolling the
first study participant. Approval of both the protocol
and informed consent documents were also obtained
from the institutional review board of each
participating institution prior to enrolling study
participants at the respective site. In addition to
providing important clinical and mechanistic
information, this investigation will inform the scientific
merit and feasibility of a phase III trial on ASA as an
ALI prevention agent. The findings of this
investigation, as well as associated ancillary studies,
will be disseminated in the form of oral and abstract
presentations at major national and international
medical specialty meetings. The primary objective and
other significant findings will also be presented in
manuscript form. All final, published manuscripts
resulting from this protocol will be submitted to Pub
Med Central in accordance with the National Institute
of Health Public Access Policy.
INTRODUCTION
Acute lung injury (ALI) and the acute respira-
tory distress syndrome (ARDS) are life-
threatening syndromes that continue to
consume substantial healthcare resources and
profoundly impact on patient-important out-
comes.
1 Although recent epidemiological
studies suggest the incidence of lung injury
ARTICLE SUMMARY
Article focus
▪ The primary objective of this manuscript is to
provide the background information and method-
ology for a randomised clinical trial aiming to
test the safety and efficacy of aspirin (ASA) in
the prevention of acute lung injury (ALI) in
patients determined to be at high risk.
▪ A secondary aim of this trial is to determine if
early administration of ASA modulates plasma
mediators shown to be important in the develop-
ment of ALI and its outcomes.
▪ Third, this study will evaluate novel mechanisms
by which an antiplatelet agent ASA may modu-
late the development and progression of lung
injury in patients at risk.
Key messages
▪ This paper describes the background informa-
tion, methodology and statistical analysis plan
for the first multicentre clinical trial aiming to
test a promising ALI prevention strategy.
▪ The results of this investigation will inform the
scientific merit of a future phase III clinical trial
on ASA administration as an ALI prevention
strategy in at-risk patients.
▪ This protocol will facilitate the development of an
essential infrastructure for future clinical trials
aiming to test ALI prevention strategies.
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2 even conservative estimates
suggest the associated mortality continues to exceed 25%.
3
Beyond mortality, an episode of ALI/ARDS also substan-
tially inﬂuences the patient’s long-term outcomes with
functional deﬁcits persisting up to 5 years after the episode
of respiratory failure.
4
Importantly, the clinical syndrome of ALI generally
occurs as a complication of an initial predisposing acute
injury such as pneumonia, aspiration, sepsis, trauma, shock
or massive transfusion.
5 However, only a fraction of patients
(10–30%) with these initial injuries develop ALI/ARDS.
67
Moreover, only 30% of ALI patients fulﬁl criteria for ALI
within 6 h of presentation to the emergency department
(ED).
8 The majority of patients develop ALI a median of
two days after hospital presentation (IQR 1–4 days). This
period of time between hospital presentation and develop-
ment of ALI presents a window of opportunity for interven-
tions to prevent the development of ALI.
Recently, accumulating evidence suggests an important
role for platelets in ALI pathogenesis
9–11 and resolution.
12–14
Notably, preclinical data suggest that aspirin (ASA) can
modulate many of the platelet-mediated processes involved
in ALI development
11 15 16 and resolution.
17 18 Proposed
mechanisms for these protective effects include reduced
thromboxane A2,
9 P-selectin
19 and platelet-derived chemo-
kine (eg, CCL5 and CXCL4)
20 production, prevention of
the formation of platelet-neutrophil aggregates
9 and neutro-
phil extracellular traps,
21 22 and enhanced formation of anti-
inﬂammatory lipid mediators such as 15-epi-lipoxin A4
(ﬁgure 1).
17 Importantly, recent observational studies have
also suggested a potential preventive role for antiplatelet
ARTICLE SUMMARY
Strengths and limitations of this study
▪ A major strength of this investigation is its multicentre, rando-
mised clinical trial study design. A second strength of this investi-
gation is the use of a lung injury prediction score for the timely
identification of patients at high risk for ALI. A third strength of
this investigation is the use of a checklist for lung injury prevention
which will standardise important co-interventions in patients at
high risk for ALI thereby minimising confounding of the primary
association of interest (ASA and ALI).
▪ Limitations of this study protocol include the recognition that
many patients may have ‘injured lungs’ at the time of study ini-
tiation despite not meeting the formal criteria for ALI. In add-
ition, it is recognised that a modest proportion of the study
population may be resistant to the actions of ASA. Finally, the
time-sensitive nature of the study protocol and the high preva-
lence of ASA use at the time of hospital admission may impact
the feasibility of this work.
Figure 1 Illustration of the potential role of aspirin, lipoxins and aspirin-triggered lipoxins on the mediators of ALI development
and progression. Black arrows indicate events in ALI. Grey arrows indicate action of ASA, LXs, or ATLs. ALI, acute lung injury;
ARDS, acute respiratory distress syndrome; ASA, aspirin; ATLs, aspirin-triggered lipoxins; HO, haeme oxygenase; I-κB, nuclear
factor kappa-light-chain-enhancer of activated B-cell inhibitor; ICAM, intercellular adhesion molecule; IL-6, interleukin-6; LX,
lipoxins; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; TNF, tumour necrosis factor.
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23 24 However, the evi-
dence remains inconclusive and equipoise remains.
To further enhance our understanding of ASA’s role
in the prevention and/or mitigation of ALI, the Lung
Injury Prevention Study (LIPS) group with the support
of the US Critical Illness and Injury Trials Group
(USCIITG) as well as the National Heart, Lung and
Blood Institute (NHLBI) have designed the LIPS with
Aspirin (LIPS-A), a randomised clinical trial that aims to
test the safety and efﬁcacy of ASA in the prevention of
ALI in patients determined to be at high risk. This
paper describes the study procedures and planned ana-
lyses for this clinical trial.
METHODS AND ANALYSIS
Administrative structure
To facilitate the conduct of the present investigation, as
well as future ALI prevention studies, three specialised
centres were established. The data and statistical coordin-
ating centre, responsible for data management, random-
isation and pharmacy coordination, will reside at Mayo
Clinic in Rochester, MN. The clinical coordinating centre
(CCC), responsible for the study conduct and safety mon-
itoring, will reside at Beth Israel Deaconess Medical
Center in Boston, MA, USA. The biospecimen repository
and Knowledge Translation Center, responsible for speci-
men management as well as the LIPS score and the
checklist for lung injury prevention (CLIP) online
screening tools, will reside at Monteﬁore Medical Center
in Bronx, NY, USA. The principal investigators from these
three centres form the LIPS-A Executive Committee.
This committee will collaboratively oversee all aspects of
the study design and the protocol implementation.
Study design
To test the hypothesis that ASA is associated with a
reduced rate of incident ALI, the LIPS-A group has
designed a multicentre, double-blind, placebo-controlled,
parallel group, phase II randomised clinical trial. The
ClinicalTrials.gov registration number is NCT01504867.
An outline of the study design and study procedures
appears in ﬁgure 2.
Study population
Adult patients aged 18 years and older at high risk for
ALI on admission to the hospital will be enrolled. To
facilitate the identiﬁcation of those at high risk for ALI,
the LIPS-A will utilise the recently validated LIPS.
8
Patients will be considered at high risk of development
of ALI based on an LIPS score of 4 or greater. Patients
who fulﬁl criteria for ALI on hospital presentation or at
any point prior to randomisation will be excluded. A full
list of exclusion criteria with the justiﬁcation for each
can be seen in table 1.
Patients will be recruited from 14 clinical sites in the
USA with experience in the identiﬁcation and manage-
ment of ALI. A full list of the participating institutions as
well as each site’s primary investigator can be seen in
table A1 and are indexed on ClinicalTrials.gov. The result-
ing study population is expected to be diverse and repre-
sentative of the general population of patients at risk for
ALI such that the study ﬁndings will be externally valid
and generalisable to the broader academic community.
To facilitate patient enrolment, study coordinators at
each participating institution will screen patients in the ED
with a web-based LIPS calculator to determine each poten-
tial participant’s risk for development of ALI. Eligible
patients with an LIPS score ≥4 will be approached by study
coordinators or study investigators for informed consent.
Eligible patients will be enrolled and randomised within
12 h of hospital presentation. This will allow for maximal
recruitment within the window of opportunity for inter-
ventions to prevent ALI development as our preliminary
data show median time to ALI is 2 days after hospital
admission.
8
Interventions
Study drug: The ﬁrst dose of study drug (ASA vs
placebo) will be administered within the ﬁrst 24 h after
presentation to the hospital, either by mouth or by naso-
gastric or orogastric tube. For patients randomised to
the intervention arm, a generic ASA 325 mg one-time
loading dose on day 1 will be administered followed by
generic ASA 81 mg by mouth once daily for study days
2–7 or until hospital discharge or death, whichever
occurs ﬁrst. The intervention duration of 7 days was
chosen because >85% of ALI/ARDS cases were noted to
Figure 2 Schematic of the planned study procedures.
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ary studies.
8 In support of the dosing scheme chosen for
this investigation, a randomised clinical trial noted
low-dose ASA at 81 mg daily was effective in elevating
plasma levels of anti-inﬂammatory lipoxins and inhibit-
ing platelet thromboxane activity with only a slight
increase in effect at higher doses of ASA.
25 26 All study
medication doses (active treatment with ASA and
placebo) will be in powder form of identical colour, con-
tained within capsules that can be opened and adminis-
tered via a gastric tube.
Co-interventions: Important co-interventions will be
standardised in all study patients. To this end, the inves-
tigative team has developed a web-based, computerised,
interactive tool to standardise essential elements of care
delivery such as mechanical ventilation, aspiration pre-
cautions, infection control, ﬂuid management and trans-
fusion in patients at risk. This tool is termed CLIP.
2
A summary of the CLIP elements is listed in table 2.
Having identiﬁed high-risk patients early in the course
of the illness with the LIPS calculation and having stan-
dardised the important elements of care delivery with
the CLIP, we expect to have optimised our ability to
investigate whether ASA is a safe and effective agent in
preventing ALI.
Related conditions and variables of interest:
Additional conditions and variables of interest including
pertinent baseline demographics and clinical character-
istics such as age, sex, race, comorbidities and all LIPS
elements will also be recorded. Additional variables
Table 1 Study exclusion criteria
Exclusion criteria Justification
Antiplatelet therapy on admission or within 7 days prior to admission Inability to ethically randomise
Presented to outside hospital emergency department >12 h before arrival
at site’s facility
Inability to enrol within time frame for
possible benefit
Inability to obtain consent and randomise within 12 h of hospital presentation Inability to enrol within time frame for
possible benefit
Admitted for elective or emergency surgery Aspirin not found to benefit this group in
preliminary studies
ALI on hospital presentation or prior to randomisation Inability to adequately assess outcome
Presentation believed to be due to pure heart failure and no other known risk
factors for ALI
Inability to adequately assess outcome
Receiving mechanical ventilation through a tracheostomy tube prior to current
hospital admission (patient who is ventilator dependent)
Inability to adequately assess outcome
Bilateral pulmonary infiltrates present on admission only if the patient has a
history of interstitial lung disease that can reasonably explain the current degree
of pulmonary infiltrates present
Inability to adequately assess outcome
Allergy to aspirin or NSAIDs Intervention contraindicated
Bleeding disorder* Intervention contraindicated
Suspected active bleeding or judged to be at high risk for bleeding complications Intervention contraindicated
Presence of acute kidney injury† Intervention contraindicated
Severe chronic liver disease (Child-Pugh class C) Intervention contraindicated
Active peptic ulcer disease (within past 6 months) Intervention contraindicated
Pregnancy or breast feeding Intervention contraindicated
Inability to administer study drug Unable to administer study drug
Expected hospital stay <48 h Incomplete study procedures and
outcome data
Admitted for comfort or hospice care Incomplete study procedures and
outcome data
Patient, surrogate or physician not committed to full support (exception: a patient
will not be excluded if he/she would receive all supportive care except for attempts
at resuscitation from cardiac arrest)
Unable to assess primary outcome
Not anticipated to survive >48 h Incomplete study procedures and
outcome data
Previously enrolled in this trial Violates the statistical assumption of
sample independence
Enrolment in concomitant intervention study Potential confounding and co-enrolment
interactions
*Any disorder with known associated with increased risk of bleeding. Common disorders may include thrombocytopaenia, disseminated
intravascular coagulation, haemophilia, von Willebrand disease, oral anticoagulant therapy or advanced liver disease with associated
coagulation disorders. Platelet count <50000 or absence of platelet count in the previous 24 h to allow for assessment of platelet status.
†Acute kidney injury defined as ‘R’ or greater according to RIFLE criteria.
ALI, acute lung injury; NSAIDs, non-steroidal anti-inflammatory medications.
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that are obtained during the course of routine care,
APACHE IV scores, coadministration of statins, ACE inhi-
bitors and angiotensin-receptor blocking agents, insulin,
amiodarone or steroids; blood product administration,
daily ﬂuid status and vasopressor requirements. A full
description of the schedule of events for this study
protocol can be seen in table 3.
Outcomes
Clinical Outcomes: The primary outcome is the develop-
ment of ALI within 7 days of hospital admission. ALI will
be deﬁned as requirement for invasive mechanical venti-
lation and fulﬁlment of the American-European consen-
sus deﬁnition for ALI/ARDS.
27 Patients will be screened
daily for respiratory failure and the partial pressure of
arterial oxygen (PaO2) to fraction of inspired oxygen
(FiO2) ratio will be calculated daily for those on mechan-
ical ventilation. Patients ventilated with non-invasive venti-
lation will not be considered ALI/ARDS as our
preliminary data showed that the majority (90%) of ALI
patients are eventually intubated.
8 Investigators at each
site will review structured online training for assessment
of ALI as was used and described in the LIPS.
8 In add-
ition, de-identiﬁed chest x-rays of the ﬁrst ﬁve patients
enrolled at each site will be sent to CCC for validation by
the primary investigators. Any site with signiﬁcant devi-
ation will be retrained. Each participating centre’s princi-
pal investigator will adjudicate the diagnosis of ALI/
ARDS using standardised deﬁnitions. Patients receiving
invasive mechanical ventilation who, within a given 24-h
period, fulﬁl criteria for PaO2/FiO2<300 mm Hg, bilat-
eral inﬁltrates consistent with ALI and not completely
explained by heart failure, will be determined to have
developed ALI. Given prior data suggesting poor agree-
ment in the radiological interpretation of bilateral inﬁl-
trates on chest radiographs consistent with ALI,
28 a
secondary review of all ALI cases and a random sample of
non-ALI cases will be performed by an independent
expert investigator who is blinded to the initial ALI/
ARDS adjudication. Study participants who die or are dis-
charged from the hospital prior to day 7, and had not
met criteria for ALI at the time of death or discharge, will
be adjudicated as not having developed ALI.
Secondary clinical outcome assessments will include
changes in the lung injury score and sequential organ
failure assessment score, as well as the number of
ventilator-free days at hospital day 28 and intensive care
unit (ICU) and hospital lengths of stay. Mortality will be
assessed at discharge from the ICU, from the hospital,
and at 28 days. In addition, hospital survivors will
undergo a brief follow-up phone survey to assess func-
tional status (Barthel Index), health-related quality of life
(QOL (SF-12)) and frailty (VES-13) at 6-months and
12-months after enrolment.
Mechanistic Outcomes: Secondary analyses will include
evaluations of the mechanisms by which antiplatelet
agents (eg, ASA) may modulate the development and
progression of lung injury as well as a determination of
the value of plasma biomarkers of lung injury in the pre-
diction of ALI development in patients at risk (beyond
clinical variables). The study will examine biomarkers
previously found to be associated with the development of
ALI/ARDS in at-risk individuals (table 4). In addition, to
better understand the mechanisms by which ASA may
affect the development and progression of ALI, the study
will also examine the effect of ASA on ASA-triggered
lipoxins, plasma thromboxane and platelet–neutrophil
aggregates. As it is likely that other important biomarkers
in ALI may be identiﬁed in the future, plasma from con-
senting patients will be banked at the biorepository for
future studies. Blood samples will be obtained at baseline
(after randomisation and before initiation of study inter-
vention), on day 2 of study (approximately 24 h after the
ﬁrst dose of study drug) and on day 4 of study (any time
during day 4). For patients who provide consent relating
to future genetic analyses, appropriate samples will be
obtained.
Sample size estimation
The primary hypothesis for this investigation is that ASA
(when compared to placebo) will result in a lower rate
of incident ALI at day 7 following randomisation. To
Table 2 Elements of CLIP
CLIP elements Definition
Lung protective
mechanical
ventilation
Tidal volume between 6 and 8 ml/kg
predicted body weight and plateau
pressure <30 cm H2O; PEEP
≥5c mH 2O, minimise FiO2 (target
oxygen saturation 88–92% after early
shock)
Aspiration
precautions
Rapid sequence intubation supervised
by experienced providers, elevated
head of the bed, oral care with
chlorhexidine, gastric acid
neutralisation in those not receiving
tube feeds
Adequate empiric
antimicrobial
treatment and
source control
According to suspected site of
infection, healthcare exposure and
immune suppression
Limiting fluid
overload
Modified ARDSNet FACTT protocol
after early shock (first 12 h)
Restrictive
transfusion
Haemoglobin target >7 g/dl in the
absence of acute bleeding and/or
ischaemia
Appropriate
handoff of
patients at risk
Providers taking care of patients at risk
who require ICU admission will
complete a structured handoff to the
ICU team to continue with CLIP
protocol for the duration of ICU stay
ARDSNet, Acute Respiratory Distress Syndrome Network; CLIP,
checklist for lung injury prevention; FACTT, fluid and catheter
treatment trial; FiO2, fraction of inspired oxygen concentration;
ICU, intensive care unit; PEEP, positive end-expiratory pressure.
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LIPS-A: ProtocolTable 3 Schedule of events
Event
Time of presentation
until first dose
(screen/baseline)
First dose until
end of that
calendar day
(Day 1)
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7
7d a y s
after last
dose
Hospital discharge or
study Day 28,
whichever comes first 6 months 12 months
Informed consent X
Inclusion/exclusion
criteria
X
Pregnancy test in
women of childbearing
potential
X
Demographics X
Medical history X
LIPS score X
Randomisation X
Study drug
administration
X XXXXXX
Clinical outcome
assessment
X X XXXXXX
Safety labs: Cr and Hb X X XXXXX
Clinical data as
available: labs, ABG
X X XXXXXX
CXR/ABG* X X XXXXX
CLIP X X X XXXXX
AE/SAE monitoring X X XXXXXX X
Survival XX
Plasma biomarkers
of ALI
XX X
SF-12 X XX
Barthel Index X XX
Vulnerable Elders
Survey
X XX
Brussels/SOFA
composite
X
*Chest x-ray (CXR) required on days 1–7 ONLY IF patient is intubated, and DOES NOT have ALI/ARDS already, AND there is clinical evidence of worsening respiratory status defined as:
▪ Previous P/F ratio≥300, with current P/F ratio<300 and no CXR within 24 h.
▪ Prior P/F ratio<300 and the P/F ratio has fallen more than 10% AND no CXR within 24 h.
▪ In cases where an ABG is not available, the research team should obtain an ABG only if the S/F ratio falls below 315 consistently. The P/F ratio obtained from that ABG
will be used to determine whether a CXR needs to be obtained (as per criteria outlined above).
▪ If change in P/F ratio triggers the need for a CXR or ABG as above, sites have 24 h to conduct the necessary procedure. An ABG or CXR obtained by the clinical team
during that time period is also acceptable and obviates the need to obtain said procedure for the research study.
ABG, arterial blood gas; AE, adverse events; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CLIP, checklist for lung injury prevention; Cr, creatinine; Hb,
haemoglobin; LIPS, Lung Injury Prevention Study; LIS, lung injury severity score; SAE, serious adverse events; SF-12, 12-Item Short-Form Health Survey; SOFA, sequential
organ failure assessment.
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ladequately address this hypothesis, the sample size is
estimated to be 200 participants per group (400 total).
The assumptions involved in this calculation include the
following: (1) the hypothesised placebo response rate
will be 18%,
8 (2) the minimum clinically relevant effect
is 10 percentage points, and (3) the type I error rate
(α)=0.10 (two-sided; ﬁnal α=0.0889 after interim analysis
at 50% information fraction using O’Brien-Fleming-like
αspending function). To be conservative during sample
size estimation, the null proportion was shifted upwards
to 25% (ie, towards the region of maximum binomial
variance) so that the initial sample size estimates are
based on 25% vs 15%. A χ
2 test of proportions at the
α=0.10 level of signiﬁcance will have 80% power to
detect the 10 percentage point difference with 197 parti-
cipants per group. Overall recruitment is rounded to
200 participants per group (400 total) to allow for
minor attrition, although attrition is not expected to
affect the ascertainment of primary outcome. At the
hypothesised level of 18% vs 8% and with the α adjusted
for multiple interim looks, power with 200 participants
per group is 90%. Thus, for the primary analysis 400
total participants randomised 1:1 to placebo or ASA is
anticipated to yield sufﬁcient power to detect a clinically
relevant difference in the incidence of ALI.
The Data and Statistical Coordinating Center will
prepare weekly reports on the accrual process for the
trial. The reports, which will be reviewed on the weekly
executive committee calls, will include summarisation of
screening and randomisation metrics. Detailed descrip-
tions of exclusion criteria for disqualiﬁed study candi-
dates will be provided and reviewed as well. Each clinical
centre has a target enrolment of two randomised partici-
pants per month. The reports will include a comparison
of observed versus expected accrual, by clinical centre
and overall for the trial. The randomisation perform-
ance of each clinical centre will be disseminated
monthly to all study personnel through a study newslet-
ter. If site-speciﬁc enrolment concerns are identiﬁed,
methods for addressing these issues will be evaluated by
the executive committee working with the site of inter-
est. If a more pervasive and sustained gap between
expected and observed participant accrual is identiﬁed,
potential modiﬁcations to the inclusion and exclusion
criteria of the protocol will be discussed. Any amend-
ments to the inclusion and/or exclusion criteria
deemed necessary by the executive committee will
require approval by the Data and Safety Monitoring
Board (DSMB) as well as the institutional review board
(IRB) of each participating institution before implemen-
tation. If enrolment remains below plan, the inclusion
of additional clinical sites will be considered as well.
Randomisation and blinding
LIPS-A will utilise centralised randomisation software
hosted by the Data and Statistical Coordinating Center.
Randomisation through the electronic data manage-
ment system will be enabled upon electronic veriﬁcation
of inclusion and exclusion criteria and enrolment of the
study participant by the clinical site investigators.
Enrolled participants will be randomised in a 1:1 ratio to
the ASA or placebo treatment arm using dynamic mini-
misation
29 with a second guess probability of 0.2.
Randomisation will be stratiﬁed by centre. To maintain
the double blind for the study, only the research
pharmacist at each centre will have electronic access to
the unblinded treatment code for study medication
preparation and dispensing. The rest of the site investi-
gators and coordinating centres will be blinded to the
actual treatment assignment. Emergency unblinding is
available electronically and through dispensing records
at each pharmacy.
In the event the electronic randomisation system is not
functioning, the research pharmacist at each centre has a
sealed emergency randomisation kit to enable ofﬂine
randomisation. A manual of operation governs the use of
the emergency randomisation process. Brieﬂy, prior to
use of the emergency process, approval of the coordinat-
ing centres is required. All attempts will be made to
recover the system prior to the use of the ofﬂine
Table 4 Plasma biomarkers in ALI/ARDS
Plasma biomarker Importance in ALI/ARDS development
Associated outcomes other
than ALI/ARDS
Surfactant protein-D
44–46 Reflect injury and ↑ permeability of alveolar
epithelium
VFD, organ failure
Receptor for advanced glycation end
products
47–49
Reflects endothelial activation and injury VFD,
49 organ failure,
49 ARDS
after lung transplant
47
Intercellular adhesion molecule-1
44 50–53 Reflects endothelial activation and injury VFD,
51 organ failure
51
Interleukin-6
44 54–56 Inflammation VFD,
55 organ failure
55
Interleukin-8
44 48 50 54–56 Inflammation VFD,
55organ failure
55
Plasminogen activator inhibitor-1
44 50 57–61 Activation of coagulation and inhibition of
fibrinolysis
VFD,
61 organ failure
61
von Willebrand factor
44 48 60 62 63 Reflects endothelial activation and injury Organ failure
Protein C
44 50 59 61–64 Activation of coagulation and inhibition of
fibrinolysis
ARDS after lung transplant,
47
VFD,
61 organ failure
61
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; VFD, ventilator-free days.
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electronic data management system will be updated to
reﬂect the treatment assignment using the identiﬁcation
number contained within the randomisation kit.
Statistical methods
Conditional logistic regression will be used to test the
primary hypothesis that early ASA administration will
decrease the rate of ALI development. Clinical site will be
treated as the stratiﬁcation variable and conditioned out
of the estimating equations. This approach is optimal in a
clinical trial setting as it provides a test of null hypothesis
that the ALI incidence is equal in the two treatment
group and estimates the association in the event the null
hypothesis is rejected (through the conditional OR esti-
mate). SAS PROC LOGISTIC (Cary, North Carolina,
USA) will be used for estimation of the primary model.
This analysis will be supplemented by the Cochran-
Mantel-Haenszel stratiﬁed analysis with ORs computed
for each site. The Breslow-Day test will be used to
examine the data for potential effect modiﬁcation (ie, a
‘site effect’). In the event there is signiﬁcant site-to-site
variability in the estimated effect, stratiﬁed results will be
reported for this phase II study. Evidence of heterogen-
eity of response at this phase of study will yield invaluable
preliminary data for the planning of future changes.
Planned interim analyses will be conducted at 50% of
study participants enrolled. With the O’Brien-Fleming-like
stopping boundaries, a ﬁnal adjusted α of 0.08885 is antici-
pated; however, the ﬁnal value may be changed depending
on unplanned interim analyses (conducted at the request
of the DSMB) or slight deviations from the anticipated
information milestones (0.5 and 1). Stopping boundaries
will be estimated using the LD Bounds package for the
Rs y s t e m .
For the remaining continuous and dichotomous sec-
ondary endpoints, treatment group comparisons will be
performed with respect to clinical outcomes as well as
important prognostic factors at screening, baseline and
individual follow-up time points during the study duration.
For continuous variables (eg, age, weight and laboratory
assays), linear model techniques including t-tests, analysis
of variance and analysis of covariance will be applied.
Non-parametric procedures (eg, the Wilcoxon rank sum
test), will be used if data are not normally distributed and
transformations of the data are not considered useful.
Standard techniques for categorical data will be applied,
including Fisher’se x a c tt e s t ,P e a r s o nχ
2 procedures,
weighted least squares and logistic regression analysis.
Longitudinal (or serially measured) endpoints will be
evaluated by generalised linear models and linear
mixed. Repeated measure analyses of binary endpoints
will be analysed using generalised estimating equations
methods which do not require imputation of missing
values, provided the data are ignorable missing.
30
Continuous-dependent variables will utilise the mixed
model approach with emphasis on evaluating the trajec-
tories of values over time. However, early improvement
in these parameters may suggest a supportive, stabilising
role for ASA as a treatment option in patients at high
risk of ALI. For the primary analysis, the clinical centre
will be treated as a ‘nuisance’ parameter and condi-
tioned out of the estimation routine. For secondary ana-
lyses, the clinical centre will be used as a ﬁxed covariate
to account for differences across sites.
The safety endpoints (see below Adverse outcomes
section) will be examined for all participants in the
safety evaluable analysis set. Safety endpoints will include
expected clinical events, including death, for this patient
population and summarised by the treatment group.
Also, all serious and unexpected adverse events will be
summarised by the treatment group. Fisher’s exact test
will be used to estimate treatment differences in the inci-
dence of each speciﬁed adverse event. No adjustments
will be made for multiple hypothesis evaluations of
safety endpoints. Adverse events will be summarised with
groupings by body system. Other safety data (eg, labs
and assay data) will be listed, and when appropriate,
summarised in tabular or graphical format.
Data quality and management
This investigation will utilise the Medidata Rave system for
data management and storage as well as to assist with the
randomisation procedures. This product has been
designed to facilitate multicentre clinical trials conducted
under 21 Code of Federal Regulations (CFRs) Part 11
requirements. This secure, web-based system provides
robust data validation routines, custom reporting and
straightforward integration with statistical software packages
such as SAS (utilised for this investigation). The system is
coupled with an integrated randomisation module that
uses a multidimensional dynamic allocation algorithm to
minimise imbalances across multiple dimensions including
overall study, sites, factors and cross-factor strata. Speciﬁc
details regarding the randomisation process are given
above.
ETHICS AND DISSEMINATION
Adverse outcomes
Safety data including adverse events such as gastrointes-
tinal ulcers, bleeding from any site, gastrointestinal dis-
comfort, wheezing, rash, hives, angioedema, tinnitus
and mortality will be recorded. Adverse events will be
deﬁned as ‘unexpected,’‘ expected,’ and ‘serious.’ As
our patient population is by deﬁnition ‘critically ill,’ it is
expected that they will have a number of unrelated
adverse health events during the course of their hospital
stay. Therefore, we will limit the scope of our adverse
event monitoring and recording to the following:
1. Serious adverse events (SAEs) will be deﬁned as
▸ Death, believed to be related to the study medi-
cation or procedures, or a death that is unex-
pected considering the acuity of a patient.
▸ A life-threatening experience believed to be
r e l a t e dt ot h es t u d ym e d i c a t i o no rp r o c e d u r e s .
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LIPS-A: Protocol▸ Persistent or signiﬁcant disability or incapacity
that is of greater frequency or severity than
what would be normally expected in the course
of critical illness.
▸ An event that jeopardises the human subject
and may require medical or surgical treatment
to prevent one of the preceding outcomes and
is not expected in the course of critical illness.
2. Adverse events possibly related to ASA administration
will be deﬁned as
▸ Anaphylaxis/allergic reaction.
▸ Gastrointestinal bleed/bleeding complications.
▸ Transfusion requirements for suspected
bleeding.
▸ Acute kidney injury, deﬁned as RIFLE stage ‘I’
or greater.
▸ Tinnitus.
▸ Reye’s syndrome.
Role of the data safety and monitoring board
Reporting of SAEs will be conducted through the CCC.
All centres will report SAEs within 24 h of discovering
the presence of the SAE. The CCC will report all poten-
tially related SAEs to the DSMB and to NHLBI within
7 days of discovery. A summary report of the events will
be provided to the DSMB prior to each DSMB meeting,
at least every 6 months. Safety oversight will be under
the direction of a DSMB whose members will be inde-
pendent from the study operations. The safety endpoints
will be examined for all eligible patients who sign
informed consent and are enrolled in the study on an
intent-to-treat basis. Safety endpoints will include
expected clinical events, including death, for this patient
population and summarised by the treatment group. All
serious and unexpected adverse events will be sum-
marised by the treatment group as well.
Ethics approval
Approval of the protocol was obtained from the data
safety and monitoring board as well as from NHLBI
prior to enrolling the ﬁrst study participant. In add-
ition, approval of both the protocol and informed
consent documents was required and obtained from
the institutional review board of each participating
institution prior to enrolling study participants at the
respective study site. To ensure that each participating
institution’s informed consent documentation com-
plied with NHLBI requirements and the CFRs Title 21
Part 50 Section 50.25, all informed consent forms
were reviewed and approved by the CCC. Ofﬁcial
documentation of all IRB approvals and all ﬁnalised
informed consent forms have been collected and
stored by the CCC.
Considerations for continuation to a phase III clinical trial
The decision to proceed with a phase III trial is formally
outlined as follows:
1. Initiate Phase III Study: Demonstrated efﬁcacy signal
in addition to adequate safety proﬁle. Criteria: Early
termination for beneﬁt at interim analysis or
p<0.08885 at ﬁnal analysis (α=0.10 for study). Serious
adverse event proﬁle of ASA not statistically worse
than placebo (95% CI for the relative risk of any SAE
covers the null value of RR=1.0).
2. Further Development Potentially Required: Weak efﬁ-
cacy signal. Criteria: Primary endpoint did not
achieve a priori level of signiﬁcance but there were at
least a general consistency of secondary endpoints
indicating propensity for efﬁcacy with a larger sample
size and/or more speciﬁc primary endpoint.
3. Abandon Treatment Platform: Harm (in efﬁcacy or
safety endpoints). Criteria: Study terminated early
per recommendation by DSMB for safety and/or
risk/beneﬁt ratio concerns (ie, stop for futility, harm,
unacceptable risk proﬁle, etc).
Ancillary studies
The LIPS-A group will encourage investigator-initiated
ancillary study proposals that extend or complement the
speciﬁc aims of the primary LIPS-A trial. As policy, all
proposals will be reviewed by a separate Ancillary Studies
and Publications Committee, both to ensure consistency
with the goals and conduct of the main study and evalu-
ate scientiﬁc merit and validity. Proposed studies may
utilise data and/or samples already accrued during the
LIPS-A trial or, when feasible, request additional data
collection from participating sites. The investigative and
statistical plan will be reviewed a priori, with committee
approval required before analysis begins. Where equivo-
cal, review decisions will be referred to the LIPS-A
Executive Committee. All reports, manuscripts or pre-
sentations derived from data obtained through the ancil-
lary study process will require review and approval by the
Ancillary Studies and Publications Committee prior to
submission.
Protocol funding and role of the funding sources
This study is supported by the National Institutes of
Health-National Heart Lung and Blood Institute (Grant
Number U01-HL108712-01), the Mayo Clinic Center for
Translational Science Activities (Grant Number KL2
RR024151) and the Mayo Clinic Critical Care Research
Committee. Speciﬁcally, funding has been provided by
each of these entities to support study personnel time
and effort, protocol and data management development
(Medidata Rave), sample acquisition, processing and
storage and statistical support. These funding sources
have had no speciﬁci n ﬂuence on the scientiﬁc content
of the study protocol. Similarly, the funding sources will
have no direct role in the study conduct, nor data collec-
tion, analyses or interpretation. The funding sources will
also have no role in the writing or presentation of study
results, nor decisions to submit for publication. The
ultimate authority over each of these activities will be the
executive committee of the LIPS-A study.
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We have presented the study protocol and data analysis
plans for the ﬁrst phase II, multicentre randomised
clinical trial that will test the efﬁcacy and safety of a promis-
ing ALI prevention agent. Speciﬁcally, we have hypothe-
sised that early administration of ASA to hospitalised
patients who are at high risk of ALI, will be safe and will
reduce the likelihood of progression to the full ALI
phenotype. Secondarily, this investigation will glean
important mechanistic data on ASA’s impact on the path-
ways believed important in ALI pathogenesis as well as the
potential value of relevant biomarkers in the prediction of
subsequent development of ALI. Finally, the results of this
study will provide essential information on both the scien-
tiﬁc merit and feasibility of a larger, phase III trial testing
the role of ASA in the prevention of lung injury.
The persistent difﬁculty in translating promising pre-
clinical therapies into the clinical setting has fostered
interest in the potential development of effective ALI
prevention strategies. Indeed, prevention of ALI has
been identiﬁed as a key strategic priority for invested
parties such as the NHLBI.
31 However, implementation
of protocols aiming to test potential ALI prevention
strategies have been historically hindered by an inability
to accurately predict who is at risk for ALI. Moreover,
the typically short interval between risk exposure and
development of ALI as well as the small proportion of
patients who progress to the full ALI phenotype follow-
ing an ALI-related exposure has limited the feasibility of
ALI prevention studies. In addition, the historic lack of
standardisation for numerous important co-interventions
that confound the associations of interest (eg, ventilator
management, transfusion and resuscitation practices)
has also limited our ability to test preventative strategies.
To this end, the recently validated LIPS score is a key
element of the herein described study protocol.
8
Speciﬁcally, the LIPS score is expected to facilitate the
identiﬁcation of patients at greatest risk of progressing to
ALI (an LIPS score ≥4i se x p e c t e dt oi d e n t i f yas u b g r o u p
of patients who have a risk of progressing to ALI that is
greater than 18%). In addition, it is notable that this ALI
risk assessment tool was validated using data collected
within the ﬁrst 6 h after the initial evaluation in the ED.
In an ALI prevention protocol such as described herein,
where the time to randomisation is limited to 12 h from
presentation to the ED, the ability to accurately determine
risk for ALI in such a time-efﬁcient manner is critical.
A second notable strength of the current protocol is
expected to be the implementation of the CLIP for stan-
dardising important co-interventions that may otherwise
confound our association of interest (ASA and ALI).
During the period between hospital admission and the
development of ALI, healthcare delivery factors (timely
treatment of infection and shock, appropriate administra-
tion of ﬂuid and transfusion therapies, prevention of
aspiration, avoidance of large tidal volume ventilation),
may be as important as individual biology in determining
ALI development and outcome.
32–39 Moreover, a recent
survey noted wide variation in clinical practices such as
the existence of a sepsis protocol, use of low tidal volume
ventilation, positive end-expiratory pressure and restrict-
ive transfusion practices, between hospitals and among
the ED, ICU and operating room within hospitals.
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Thus, to effectively investigate preventive strategies in
ALI, the standardisation of care delivery during the early
phase of hospitalisation would appear critical. Indeed,
the ARDSNet investigators have repeatedly shown the
value of standardisation of clinical processes for ALI
patients in clinical trials, allowing for determination of
incremental beneﬁt of new interventions.
41 42 In the
current investigation, standardisation of care with best
practices will help to reduce variability in the rates of ALI
and the intensity of lung injury (noise) due to inconsist-
encies in care delivery. The result is expected to be an
increased chance of seeing a beneﬁcial clinical or bio-
logical effect from ASA and a better assessment of the
potential side effects of ASA in this population.
Although the multicentre randomised clinical trial
design, availability of a time-efﬁcient risk assessment tool
(LIPS score) and the standardisation of important
co-interventions with CLIP, as well as the robust study
support and quality control offered through Metadata
Rave, are clear strengths of the current study protocol,
several important limitations with the planned investiga-
tion are worth being noted. Lung injury may be present at
study entry even as clinical criteria for ALI are not fulﬁlled.
Though a formal diagnosis of prevalent ALI is exclusion-
ary, the molecular machinery will have been clearly set in
motion in many of the study participants. Therefore, the
study may be more accurately characterised as a preven-
tion/early treatment trial rather than a pure prevention
trial. Nonetheless, we have attempted to focus on the early
period of ALI development by mandating a short interval
from hospital presentation to randomisation (12 h) and a
similarly short interval from hospital presentation to
administration of the ﬁrst study dose (24 h). In addition,
the study will exclude patients who presented to an
outside hospital ED more than 12 h before arrival at the
enrolling site’s facility. The study will also exclude those
with ALI on hospital presentation or prior to randomisa-
tion as well as those who are receiving mechanical ventila-
tion through a tracheostomy tube prior to the current
hospital admission (patient who is ventilator dependent)
or those with a history of interstitial lung disease with
chronic pulmonary inﬁltrates that may mimic ALI.
A second limitation relates to the intervention of ASA
administration. Speciﬁcally, it is now well documented that
more than 10% of the population will have a variable
response to ASA or at least some form of ASA resistance.
17
These patients may not beneﬁtf r o mA S A ,e v e ni fA S Ac a n
modulate the development of lung injury. However, as part
of this study, we will measure plasma thromboxane, a sensi-
tive indicator of ASA resistance, to determine the preva-
lence of ASA resistance in patients at high risk of ALI. As
such, sensitivity analyses, stratifying study participants by
ASA resistance (as determined by changes in thromboxane
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ASA on ALI development is isolated to those susceptible to
the actions of ASA. A related concern is the potential inﬂu-
ence of concomitant medications that may impact on ASA’s
ability to prevent or mitigate ALI (eg, statins and corticoster-
oids). To address this concern, we will be collecting detailed
information on concomitant medications and, when neces-
sary, appropriate statistical adjustments will be made.
A third potential limitation with this study relates to a
previously recognised major barrier to ALI prevention
studies, namely feasibility. First and foremost, a substantial
proportion of the target population may be expected to
be receiving ASA on presentation to the ED, an exclusion
criteria for the current protocol. Notably, however, our
preliminary work suggests that upwards of two-thirds of
the target population was not on ASA prior to admission.
We also note that over the 3 months of the initial LIPS,
8
there were 800 patients who fulﬁlled study inclusion cri-
teria of LIPS score ≥4a n dd i dn o tf u l ﬁl the exclusion cri-
teria of pre-existing ASA use, prevalent ALI and elective
surgery. Therefore, we believe that with 14 proposed sites
and 2 years of planned enrolment, we will successfully
meet our enrolment goals of 400 total patients. Also relat-
ing to feasibility, it is possible that some sites will be chal-
lenged by the short time interval allowed for patient
enrolment as well as the short time to study drug adminis-
tration. Though a valid concern, we believe the use of the
L I P Ss c o r ea n dt h er o b u s ts u p p o r to f f e r e dt h r o u g h
Metadata Rave will greatly facilitate the enrolment and
randomisation procedures such that sites will indeed be
successful in meeting these time-sensitive challenges.
A fourth and ﬁnal limitation which deserves mention
relates to the potential toxicity of the intervention of inter-
est. Generally, ASA is well tolerated even in acutely ill, hos-
pitalised patients in whom ASA is often continued during
the hospitalisation. As an example, in a study of ASA use
up to the time of cardiac surgery, its continuation was not
associated with an increased need for transfusion therap-
ies.
43 Nevertheless, there may be injury associated with the
administration of ASA. To address this concern, patients at
risk for major complications from ASA therapy have been
excluded from the study. Multiple stopping criteria for
patients who experience adverse events have also been
incorporated into the protocol. In addition, the more
complete understanding of the safety proﬁle of an inter-
vention of interest is an important goal of all phase II
trials. In this regard, the information gleaned from this
study, adverse events included, is necessary to help decide
on the merits of proceeding to a phase III clinical trial.
CONCLUSION
This manuscript describes the study protocol and analysis
plans for the ﬁrst phase II randomised clinical trial of the
promising ALI prevention agent ASA. In addition to pro-
viding important information on the safety and efﬁcacy of
ASA in patients at high risk for ALI, the results of this trial
will also inform the scientiﬁc community regarding the
merit and feasibility of a more deﬁnitive phase III clinical
trial. Importantly, the signiﬁcance of this effort lies not
only in the speciﬁc results which will be obtained from
the study protocol, but equally in the infrastructure that
will be created to facilitate the conduct of this trial.
Speciﬁcally, the development and utilisation of innovative
methods to facilitate the early identiﬁcation of high-risk
patients with the LIPS and the standardisation of potential
confounding co-interventions with CLIP will address key
barriers to studying ALI prevention measures and is
expected to lay a framework for the meaningful conduct
of future ALI prevention studies as well.
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Table A1 Lung Injury Prevention Study with Aspirin (LIPS-A) Coordinating Center Personnel and Site Investigators
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